Madrigal Pharmaceuticals Inc

9 de out. de 2026, 19:55 UTC

Madrigal Pharmaceuticals shares fell, retracing from early gains and remaining below their 20-day moving average after three consecutive sessions of losses.

8 de out. de 2026, 20:13 UTC

Madrigal Pharmaceuticals Inc shares advanced during after-market hours on Thursday, holding steady since the previous close, though still below its 20-day moving average.

7 de out. de 2026, 19:51 UTC

Madrigal Pharmaceuticals Inc shares fell sharply, trading lower and remaining significantly below their 20-day moving average during Wednesday's market hours.

6 de out. de 2026, 19:22 UTC

Madrigal Pharmaceuticals shares are trading higher after a Phase 3 MAESTRO-NASH trial analysis showed Rezdiffra improved liver histology in patients with MASH.

29 de set. de 2026, 19:15 UTC

Madrigal Pharmaceuticals Inc shares fell significantly, reaching a low in late morning trading and remaining below the 20-day moving average.

28 de set. de 2026, 19:16 UTC

Madrigal Pharmaceuticals Inc advances as social media posts highlight buying interest ahead of Phase III data on its MASH cirrhosis treatment, despite earlier session pullback.

25 de set. de 2026, 20:12 UTC

Madrigal Pharmaceuticals Inc traded modestly lower in after-market hours, remaining near the lower end of its one-month range and below its 20-day moving average.

24 de set. de 2026, 20:07 UTC

Madrigal Pharmaceuticals shares are higher as Goldman Sachs reinstates a Buy rating with a $704 price target, while Barclays raises its target to $962.

23 de set. de 2026, 20:12 UTC

Madrigal Pharmaceuticals Inc is trading modestly higher in after-market hours, despite being below its 20-day moving average and four consecutive lower daily closes.

18 de set. de 2026, 20:06 UTC

Madrigal Pharmaceuticals Inc shares fell sharply, settling near the low end of their one-month range amid overall lower market performance on Friday.

17 de set. de 2026, 19:46 UTC

Madrigal Pharmaceuticals appointed John Reed to its board, reflecting social media skepticism about a potential J&J acquisition; shares are modestly higher since Wednesday.

16 de set. de 2026, 23:11 UTC

Madrigal Pharmaceuticals' shares are declining in after-market trading following the granting of equity inducement awards to 27 new non-executive employees.

15 de set. de 2026, 20:01 UTC

Madrigal Pharmaceuticals is trading lower amid broader market declines following a sharp drop in the NY Empire State Manufacturing Index.

10 de set. de 2026, 20:03 UTC

Madrigal Pharmaceuticals shares are lower as CEO highlights MASH sector potential at the Cantor Fitzgerald conference amid broader market volatility and ECB rate hike effects.

3 de set. de 2026, 19:36 UTC

Madrigal Pharmaceuticals is presenting five abstracts on MASH at the Paris conference on September 10, as shares trade lower today.

2 de set. de 2026, 21:01 UTC

Madrigal Pharmaceuticals is trading lower in after-market hours amid broader market weakness and unusual inactivity, though it remains above its 20-day moving average.

1 de set. de 2026, 19:36 UTC

Madrigal Pharmaceuticals shares are declining amid rising oil prices and inflation concerns. The stock initially reached a session high earlier in the session.

31 de ago. de 2026, 21:01 UTC

Madrigal Pharmaceuticals shares are lower in after-market trading, fluctuating within a narrow range amid broader market sentiment influenced by Fed Chair Kevin Warsh's remarks.

28 de ago. de 2026, 19:56 UTC

Madrigal Pharmaceuticals Inc shares are lower today, with no specific news identified. Broader market sentiment may be affected by inflation concerns from a Federal Reserve official.

27 de ago. de 2026, 21:01 UTC

Madrigal Pharmaceuticals Inc shares are higher in after-market trading, continuing a cumulative gain since Thursday's close, with no specific news identified.

26 de ago. de 2026, 22:01 UTC

Madrigal Pharmaceuticals shares are higher in after-market trading, reaching a peak of 1.05% above Wednesday's close, with no specific news identified.

21 de ago. de 2026, 19:46 UTC

Madrigal Pharmaceuticals is lower in Friday's session, retracing from an earlier peak amid broader market pressures from rising Treasury yields and inflation concerns.

20 de ago. de 2026, 23:46 UTC

Madrigal Pharmaceuticals shares are lower in after-market trading. Broader market declines are attributed to rising crude oil prices and geopolitical tensions.

18 de ago. de 2026, 19:56 UTC

Madrigal Pharmaceuticals shares are lower today amid rising Treasury yields, which may be influencing investor sentiment. Earlier, the stock pulled back from a session high.

17 de ago. de 2026, 19:35 UTC

Madrigal Pharmaceuticals is trading higher today, continuing gains since Friday's close, despite no specific company news driving the upward movement.

14 de ago. de 2026, 19:26 UTC

Madrigal Pharmaceuticals launches a Phase 2a study for resmetirom. Shares are lower today, pulled back from earlier gains amid broader market concerns over retail sales.

13 de ago. de 2026, 21:01 UTC

Madrigal Pharmaceuticals Inc shares are higher in after-market trading, showing notable movement since Thursday's close, though no specific news explains the price action.

12 de ago. de 2026, 21:01 UTC

Madrigal Pharmaceuticals shares are higher in after-market trading. Positive market sentiment follows comments on CPI reports that may impact Federal Reserve interest rate decisions.

10 de ago. de 2026, 19:16 UTC

Madrigal Pharmaceuticals Inc shares are higher, despite no specific news. Broader market conditions reflect a decline in U.S. stock futures amid job data.

7 de ago. de 2026, 20:02 UTC

Madrigal Pharmaceuticals shares are lower during Friday's session, continuing a decline since Thursday. The stock remains below its 20-day moving average.